LOU064: Clinical Trials

14 trials of LOU064, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 recruiting, 5 active not recruiting, 2 completed. 14 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 314Recruiting 7, Active not recruiting 5, Completed 2

Follow LOU064: new trials by email Literature Review of LOU064 trials Research Report on LOU064

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Remibrutinib, Placebo - Chronic Pruritus of Unknown Origin
Phase 3RecruitingNovartis Pharmaceuticals1802026-10-072026-11-09
Investigation of a Remibrutinib- and Omalizumab-based Treatment Algorithm in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Within 24 Weeks
Remibrutinib, Omalizumab - Chronic Spontaneous Urticaria
Phase 3RecruitingNovartis Pharmaceuticals3822026-09-212026-11-09
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
Remibrutinib, Placebo - IgE-Mediated Food Allergy, Peanut Allergy
Phase 3RecruitingNovartis Pharmaceuticals5762026-08-272026-11-09
A Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
Remibrutinib, Placebo - Chronic Pruritus of Unknown Origin
Phase 3RecruitingNovartis Pharmaceuticals1802026-08-242026-11-09
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Remibrutinib - Hidradenitis Suppurativa
Phase 3RecruitingNovartis Pharmaceuticals7102026-07-102026-11-09
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Remibrutinib (blinded), Placebo, Remibrutinib (Open label) - Secondary Progressive Multiple Sclerosis (SPMS)
Phase 3RecruitingNovartis Pharmaceuticals12752025-11-112026-10-13
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Remibrutinib oral treatment, Ocrelizumab - Relapsing Multiple Sclerosis
Phase 3RecruitingNovartis Pharmaceuticals4002025-06-232026-10-26
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa
Phase 3Active not recruitingNovartis Pharmaceuticals5652025-03-202026-10-15
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Remibrutinib (Blinded), Placebo, Remibrutinib (Open Label) - Generalized Myasthenia Gravis
Phase 3Active not recruitingNovartis Pharmaceuticals1802025-02-072026-09-28
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
Remibrutinib Dose A, Remibrutinib Dose B, Placebo 1 - Hidradenitis Suppurativa
Phase 3Active not recruitingNovartis Pharmaceuticals5882025-01-312026-10-15
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
LOU064 - Chronic Spontaneous Urticaria
Phase 3CompletedNovartis Pharmaceuticals1442023-04-052025-10-16
A Safety and Efficacy Study of Remibrutinib in the Treatment of CSU in Japanese Adults Inadequately Controlled by H1-antihistamines
LOU064 - Chronic Spontaneous Urticaria
Phase 3CompletedNovartis Pharmaceuticals712022-01-152025-04-08
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)
Remibrutinib, Teriflunomide - Relapsing Multiple Sclerosis
Phase 3Active not recruitingNovartis Pharmaceuticals10002021-12-162026-08-18
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
Remibrutinib, Teriflunomide - Relapsing Multiple Sclerosis
Phase 3Active not recruitingNovartis Pharmaceuticals10072021-12-132026-11-12

Conditions studied

Chronic Urticaria (3)  ·  Hidradenitis Suppurativa (3)  ·  Charcot-Marie-Tooth disease, Type 1F (2)  ·  Dermatitis (2)  ·  Hidradenitis (2)  ·  Recurrence (2)  ·  Egg Hypersensitivity (1)  ·  Food Hypersensitivity (1)  ·  Milk Hypersensitivity (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Chronic Progressive (1)  ·  Myasthenia Gravis (1)  ·  Peanut Hypersensitivity (1)

Sponsors

Novartis Pharmaceuticals (14)

Countries

United States (12)  ·  Canada (11)  ·  Argentina (10)  ·  Spain (9)  ·  Germany (8)  ·  China (7)  ·  France (7)  ·  Italy (7)  ·  Poland (7)  ·  Mexico (6)  ·  Slovakia (6)  ·  United Kingdom (6)  ·  Australia (5)  ·  Brazil (5)  ·  Czechia (5)

Results publications

PMID 41712058, PMID 42915009

NIH funding

2023 (3), 2025 (3)